Boeing Wins $20 Billion Navy Fighter Contract as Broad Market Rally Lifts Tech and Biotech Stocks

Boeing shares rose more than 3% on Wednesday after the company beat out Northrop Grumman to win a U.S. Navy contract worth more than $20 billion to develop and build the sixth-generation F/A-XX Strike Fighter, a stealthy jet intended to replace the Navy's fleet of F/A-18 Super Hornets. The win delivered a major boost to Boeing, which has faced years of operational and financial strain, and the stock's gain was among the sharper single-day moves in the defense sector on the session.

Alphabet shares also jumped, rising roughly 2.2%, as investors weighed the company's AI infrastructure spending trajectory and the competitive depth of its Gemini platform against ongoing regulatory pressure, including a pending appeal of a 3 billion euro European Commission fine related to search self-preferencing practices.

Applied Materials attracted fresh attention tied to AI-driven semiconductor demand, even as Morgan Stanley had trimmed its price target on the stock to $563 from $642 just days earlier on September 28. Super Micro Computer shares were active on Wednesday amid continued investor focus on the AI server buildout, where the company remains a key hardware supplier.

Several smaller-cap names posted outsized gains. Q32 Bio surged after analysts at Jefferies and Clear Street initiated coverage with Buy ratings. Spyre Therapeutics rallied on the back of positive Phase 2 SKYLINE trial data for its IBD drug candidate SPY001, which showed best-in-class efficacy potential. MongoDB climbed as investors looked ahead to an upcoming earnings catalyst, with analyst consensus targets revised sharply higher and a high-end price target of $560 cited by tracked analysts. Rocket Lab, Monday.com, and Rumble also rallied, while Lucid Group shares moved on continued focus on the EV maker's liquidity position, which stood at $3.0 billion at the end of the second quarter after the company produced 4,774 vehicles and delivered 3,953 in that period.